5.94 USD
+0.02 (+0.34%)
5.94 USD
0 (0%)
Taking everything into account, NEOG scores 3 out of 10 in our fundamental rating. NEOG was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While NEOG seems to be doing ok healthwise, there are quite some concerns on its profitability. NEOG has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
NEOG had positive earnings in the past year.
In the past year NEOG had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: NEOG reported negative net income in multiple years.
NEOG had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -30.88%, NEOG is in line with its industry, outperforming 42.55% of the companies in the same industry.
NEOG has a Return On Equity (-49.23%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -49.23% | ||
| ROIC | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NEOG has a Gross Margin of 46.39%. This is comparable to the rest of the industry: NEOG outperforms 40.43% of its industry peers.
NEOG's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for NEOG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
2. Health
2.1 Basic Checks
NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NEOG remains at a similar level compared to 1 year ago.
Compared to 5 years ago, NEOG has more shares outstanding
The debt/assets ratio for NEOG is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.78, we must say that NEOG is in the distress zone and has some risk of bankruptcy.
NEOG's Altman-Z score of 0.78 is in line compared to the rest of the industry. NEOG outperforms 50.00% of its industry peers.
A Debt/Equity ratio of 0.37 indicates that NEOG is not too dependend on debt financing.
NEOG has a Debt to Equity ratio of 0.37. This is comparable to the rest of the industry: NEOG outperforms 47.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.78 |
ROIC/WACCN/A
WACC7.63%
2.3 Liquidity
NEOG has a Current Ratio of 3.58. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
NEOG's Current ratio of 3.58 is fine compared to the rest of the industry. NEOG outperforms 64.89% of its industry peers.
NEOG has a Quick Ratio of 2.26. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NEOG (2.26) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.58 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
The earnings per share for NEOG have decreased strongly by -25.00% in the last year.
The earnings per share for NEOG have been decreasing by -10.20% on average. This is quite bad
Looking at the last year, NEOG shows a decrease in Revenue. The Revenue has decreased by -2.77% in the last year.
NEOG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.43% yearly.
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%
3.2 Future
The Earnings Per Share is expected to grow by 7.29% on average over the next years.
Based on estimates for the next years, NEOG will show a small growth in Revenue. The Revenue will grow by 0.76% on average per year.
EPS Next Y-25.82%
EPS Next 2Y2.51%
EPS Next 3Y6.43%
EPS Next 5Y7.29%
Revenue Next Year-7.61%
Revenue Next 2Y-3.02%
Revenue Next 3Y-1.03%
Revenue Next 5Y0.76%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 19.80 indicates a rather expensive valuation of NEOG.
Compared to the rest of the industry, the Price/Earnings ratio of NEOG indicates a rather cheap valuation: NEOG is cheaper than 81.38% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.15. NEOG is valued slightly cheaper when compared to this.
NEOG is valuated rather expensively with a Price/Forward Earnings ratio of 17.13.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NEOG indicates a rather cheap valuation: NEOG is cheaper than 82.45% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.22. NEOG is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.8 | ||
| Fwd PE | 17.13 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 76.60% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 19.65 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.51%
EPS Next 3Y6.43%
5. Dividend
5.1 Amount
NEOG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.94
+0.02 (+0.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners112.45%
Inst Owner Change2.38%
Ins Owners0.42%
Ins Owner Change84.05%
Market Cap1.29B
Revenue(TTM)886.89M
Net Income(TTM)-1.04B
Analysts76.36
Price Target7.78 (30.98%)
Short Float %9.67%
Short Ratio4.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)30.72%
Min EPS beat(2)-34.64%
Max EPS beat(2)96.08%
EPS beat(4)2
Avg EPS beat(4)15.53%
Min EPS beat(4)-34.64%
Max EPS beat(4)96.08%
EPS beat(8)2
Avg EPS beat(8)-1.35%
EPS beat(12)4
Avg EPS beat(12)52.58%
EPS beat(16)5
Avg EPS beat(16)29.73%
Revenue beat(2)1
Avg Revenue beat(2)0.03%
Min Revenue beat(2)-0.4%
Max Revenue beat(2)0.46%
Revenue beat(4)1
Avg Revenue beat(4)-0.95%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)0.46%
Revenue beat(8)2
Avg Revenue beat(8)-0.99%
Revenue beat(12)3
Avg Revenue beat(12)-0.84%
Revenue beat(16)3
Avg Revenue beat(16)-1.21%
PT rev (1m)17.31%
PT rev (3m)17.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.33%
EPS NY rev (1m)77.78%
EPS NY rev (3m)-2.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.63%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)0.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.8 | ||
| Fwd PE | 17.13 | ||
| P/S | 1.46 | ||
| P/FCF | N/A | ||
| P/OCF | 14.83 | ||
| P/B | 0.61 | ||
| P/tB | N/A | ||
| EV/EBITDA | 19.65 |
EPS(TTM)0.3
EY5.05%
EPS(NY)0.35
Fwd EY5.84%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.4
OCFY6.74%
SpS4.08
BVpS9.75
TBVpS-1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number8.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -49.23% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.39% | ||
| FCFM | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
F-Score3
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 8.03 | ||
| Cap/Depr | 75.94% | ||
| Cap/Sales | 10.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 88.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.58 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 0.78 |
F-Score3
WACC7.63%
ROIC/WACCN/A
Cap/Depr(3y)85.8%
Cap/Depr(5y)97.5%
Cap/Sales(3y)10.58%
Cap/Sales(5y)8.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
EPS Next Y-25.82%
EPS Next 2Y2.51%
EPS Next 3Y6.43%
EPS Next 5Y7.29%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%
Revenue Next Year-7.61%
Revenue Next 2Y-3.02%
Revenue Next 3Y-1.03%
Revenue Next 5Y0.76%
EBIT growth 1Y-147.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.85%
EBIT Next 3Y34.71%
EBIT Next 5Y20.44%
FCF growth 1Y39.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.3%
OCF growth 3Y-5.05%
OCF growth 5Y-7.47%
NEOGEN CORP / NEOG FAQ
What is the fundamental rating for NEOG stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEOG.
Can you provide the valuation status for NEOGEN CORP?
ChartMill assigns a valuation rating of 4 / 10 to NEOGEN CORP (NEOG). This can be considered as Fairly Valued.
How profitable is NEOGEN CORP (NEOG) stock?
NEOGEN CORP (NEOG) has a profitability rating of 3 / 10.
What is the earnings growth outlook for NEOGEN CORP?
The Earnings per Share (EPS) of NEOGEN CORP (NEOG) is expected to decline by -25.82% in the next year.